Author | Lightnews

Sarah Cannon Research Institute

@scri.com

31 followers 1 following 60 posts

Sarah Cannon Research Institute (SCRI) is one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development.

Posts Media Videos Starter Packs

Pinned

Sarah Cannon Research Institute @scri.com · Mar 25

SCRI is transforming cancer care through groundbreaking trials at 250 locations in 24 states. Join us in advancing therapies and offering hope.

Watch how we collaborate to make a difference.

#CancerResearch #ClinicalTrials #NewHope #SCRI
scri.com

Sarah Cannon Research Institute @scri.com · 4d

PHAROS trial update: Half of treatment-naïve patients with BRAF V600E–mutant NSCLC treated with encorafenib + binimetinib are alive at 4 years.
Shoutout to Dr. Melissa Johnson for her leadership in advancing targeted therapy!
🔗 www.ajmc.com/view/long-te...
#CancerCare #Oncology #TargetedTherapy

Long-Term Data for PHAROS Show Half of Treatment-Naïve Patients Receiving Encorafenib Plus Binimetinib Alive at 4 Years | AJMC

A mini oral session at ESMO of targeted therapy in non-small cell lung cancer included treatments that showed effectiveness in brain metastases.

www.ajmc.com

Sarah Cannon Research Institute @scri.com · 5d

The future of oncology is here: AI-powered decisions, precision medicine, and collaborative care models. At #PCOC2025, experts—including Dr. Vivek Subbiah—explored how these innovations will improve patient outcomes.

🔗 www.ajmc.com/view/experts...
#HealthcareInnovation #Oncology #AI

Experts Highlight AI, Innovation, and Collaboration as Key PCOC Takeaways | AJMC

Five experts share their key takeaways from Patient-Centered Oncology Care® (PCOC) 2025, highlighting AI integration and collaboration to improve care.

www.ajmc.com

Sarah Cannon Research Institute @scri.com · 18d

Your breast cancer risk is personal—and understanding it is powerful.
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI

Sarah Cannon Research Institute @scri.com · 21d

We’re celebrating Dr. Howard “Skip” Burris’s remarkable career as he prepares to retire as President & CMO of SCRI.
His legacy: 850+ first-in-human trials, countless lives impacted. 💙

Welcome new leaders and read the full update:
www.scri.com/news/scri-an...

Sarah Cannon Research Institute @scri.com · 25d

At 45, Bryan was diagnosed with advanced prostate cancer.
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch

Sarah Cannon Research Institute @scri.com · 28d

Bill, 76, joined a clinical trial at SCRI to treat stage IV prostate cancer. His goal: dance at his daughter’s wedding. ✅
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer

Sarah Cannon Research Institute @scri.com · Sep 26

🎧 SCRI’s Dr. Garmezy & Dr. Bupathi share expert insights on treating variant histologies in GU cancers at #WorldGU2025 on Oncology Decoded.
🔗 www.cancernetwork.com/view/episode...
#SCRI #CancerResearch #GUOncology #OncologyDecoded

Episode 12: Variant Histology Treatment Considerations From World GU 2025 | CancerNetwork

Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.

www.cancernetwork.com

Sarah Cannon Research Institute @scri.com · Sep 25

Mary is proof that hope and research go hand in hand.
She’s in a clinical trial for IV #ovariancancer at #SCRI at Mary Crowley—and her disease has remained stable since March.
She’s walked the Camino de Santiago, joined the Lourdes Pilgrimage, & got a tattoo to celebrate it all. #PatientStories

Sarah Cannon Research Institute @scri.com · Sep 19

Dr. Hans Lee & Dr. Kris Patel from SCRI Oncology share how new therapies like CAR T-cell treatment are changing lives.

📺 Watch the News Channel 5 segment: www.youtube.com/watch?v=hg4_...
#BloodCancerAwareness #LymphomaAwareness #CancerCare #SCRI

How Blood Cancer Research Is Advancing Treatment | Dr. Hans Lee & Dr. Kris Patel on News Channel 5

YouTube video by Sarah Cannon Research Institute

www.youtube.com

Sarah Cannon Research Institute @scri.com · Sep 12

Dr. Jason Henry featured on @DenverChannel discussing early data from a promising #pancreaticcancer vaccine.
“This is one of the most exciting times in pancreatic cancer research in the last 100 years.”
#SCRI #CancerResearch #ClinicalTrials
www.denver7.com/lifestyle/he...

Early data for new pancreatic cancer vaccine generating hope among patients, researchers

Early data for a new vaccine for pancreatic cancer is generating some hope among patients and researchers.

www.denver7.com

Sarah Cannon Research Institute @scri.com · Sep 5

“Prostate cancer is often treatable—if caught early.”
Dr. Benjamin Garmezy shares why early screening matters and how new therapies are offering hope.
🎥 Watch the clip: youtu.be/tMnvf31VWN8
#ProstateCancerAwareness #MensHealth #CancerResearch #SCRIOncology

What You Need to Know About Prostate Cancer Awareness | Dr. Benjamin Garmezy on News Channel 5

YouTube video by Sarah Cannon Research Institute

youtu.be

Sarah Cannon Research Institute @scri.com · Sep 2

Joseph, a physician & mountain biking coach, was diagnosed with AML in 2023. A clinical trial at SCRI helped him return to biking, coaching, and living fully. 💬 Read his story: www.scri.com/patients/?co...
#AML #SCRI #ClinicalTrials #Hope

Sarah Cannon Research Institute @scri.com · Aug 27

New studies in ASH’s Blood Advances show significant quality-of-life gains for patients with #SickleCell & #BetaThalassemia.

From hospital beds to classrooms & workplaces, read how CRISPR is giving new opportunities to pts.

#GeneTherapy #ExaCel #CRISPR #Hematology

American Society of Hematology @ash.hematology.org · Aug 27

Gene therapy is changing lives! For patients with sickle cell disease and beta thalassemia, exa-cel means freedom from hospital visits and a renewed quality of life. 🔗 Learn more in the press release: https://bit.ly/3HTDvM8

@hfrangoul.bsky.social

Sarah Cannon Research Institute @scri.com · Aug 26

Dr. Hans Lee joins OncLive On Air to discuss FDA approval of linvoseltamab for relapsed/refractory multiple myeloma. A new option for patients with limited therapies.

🔗 www.onclive.com/view/fda-app...

#MultipleMyeloma #SCRI #FDAApproval

FDA Approval Insights: Linvoseltamab in Relapsed/Refractory Multiple Myeloma: With Nisha Joseph, MD; and Hans Lee, MD

Drs Lee and Joseph discuss the significance of the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

www.onclive.com

Sarah Cannon Research Institute @scri.com · Aug 25

Kim’s story is a powerful reminder of what clinical trials can offer.
After receiving treatment through SCRI and Alliance Cancer Specialists, today, she’s an advocate, fundraiser, and survivor.
www.scri.com/patients/?co...
#SCRI #OvarianCancerAwareness #ClinicalTrialsMatter #PatientStories

Sarah Cannon Research Institute @scri.com · Aug 22

Early data from a personalized mRNA vaccine shows promise in delaying recurrence in pancreatic cancer. Dr. Jason Henry shares why this is generating hope.

🔗 www.onclive.com/view/persona...
#PancreaticCancer #CancerVaccine #SCRI

Personalized Cancer Vaccine Leads to Delays in Pancreatic Cancer Recurrence

Adjuvant treatment with the personalized neoantigen vaccine, autogene cevumeran, delayed pancreatic cancer recurrence in pancreatic ductal adenocarcinoma.

www.onclive.com

Sarah Cannon Research Institute @scri.com · Aug 21

FDA accepts NDA for vepdegestrant in ER+/HER2– metastatic breast cancer. Dr. Erika Hamilton highlights the VERITAC-2 trial’s impact on this promising therapy.

🔗 www.onclive.com/view/fda-acc...
#BreastCancer #VERITAC2 #SCRI #FDAApproval

FDA Accepts NDA for Vepdegestrant in ESR1-Mutated, ER+/HER2– Breast Cancer

The FDA accepted an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer harboring ESR1 mutations after prior endocrine therapy.

www.onclive.com

Sarah Cannon Research Institute @scri.com · Aug 20

In Oncology Decoded, SCRI's Drs. Bupathi and Garmezy, discuss evolving strategies for treating urothelial carcinoma beyond first-line therapy, particularly in light of recent FDA approvals.

Listen to the episode: www.cancernetwork.com/view/episode...

Sarah Cannon Research Institute @scri.com · Aug 19

Lisa’s story is one of resilience and research.

Diagnosed with triple-negative breast cancer while pregnant, she beat the odds through a clinical trial at SCRI.
Nearly 20 years later, she’s cancer-free — and her journey continues to inspire.
www.scri.com/patients/?co...

#PatientStories

Sarah Cannon Research Institute @scri.com · Aug 18

Welcome Dr. Sarah Premji to Sarah Cannon Research Institute! As Assistant Director of Breast Cancer Research, she brings deep expertise and passion for patient-centered care.

📄 Full story: www.scri.com/news/sarah-c...
#SCRI #CancerResearch #Leadership #BreastCancer

Sarah Cannon Research Institute @scri.com · Aug 15

🧬 “AQUILA is a big trial… and there’s a trend toward improved OS.”
– SCRI expert, Dr. Burke on daratumumab for high-risk smoldering #MultipleMyeloma in Targeted Therapies in Oncology.

ODAC votes 6–2 in favor. FDA decision pending.
📖 Read: www.targetedonc.com/view/dr-burk...

Dr Burke Discusses Daratumumab in Smoldering Myeloma

John M. Burke, MD, discusses the FDA ODAC's decision on the use of daratumumab in high-risk smoldering multiple myeloma and its implications for clinical practice.

www.targetedonc.com

Sarah Cannon Research Institute @scri.com · Aug 14

85% of cancer patients stay local for care.

Now, they can access clinical trials too—thanks to partnerships with SCRI.

🎥 Watch how we’re bringing hope and innovation closer to home: youtu.be/u_Ay6R9Mj_A

#CancerCare #ClinicalTrials #SCRI #OncologyResearch #HopeCloseToHome

How Your Local Practice Fits into SCRI

Did you know that 85% of cancer patients choose to receive care in their local communities? In this video, discover how local care teams partner with the Sar...

youtu.be

Sarah Cannon Research Institute @scri.com · Aug 13

JP was diagnosed with stage IV lung cancer. He joined a clinical trial through SCRII at OHC—and responded to immunotherapy.

Now in remission, he celebrates each year with a cake and a message of hope. 🎂

#SCRI #CancerSurvivor #Immunotherapy #ClinicalResearch

www.scri.com/patients/?co...

Sarah Cannon Research Institute @scri.com · Aug 12

How do we bring #PrecisionMedicine to every cancer patient? Jason Hammonds (#TheUSOncologyNetwork) spotlights insights from Dr. Eric Lander and Andrew McKenzie on simplifying workflows, integrating trials, and empowering providers in #communityoncology.

www.targetedonc.com/view/expandi...

Expanding Precision Medicine’s Impact on All Tumor Types

Precision medicine revolutionizes cancer care, empowering patients with personalized insights and targeted therapies while addressing implementation challenges in community oncology.

www.targetedonc.com

Sarah Cannon Research Institute @scri.com · Jul 31

New from #CancerNetwork: Dr. Erika Hamilton of SCRI Oncology Partners shares insights on ADCs, CDK4/6 inhibitors & early breast cancer care from #IBC25.
🎧 Listen: www.cancernetwork.com/view/highlig...

#BreastCancer #Oncology #SCRI

Highlighting Breast Cancer Advances at IBC East

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.